{"id":5942,"date":"2026-09-23T03:22:09","date_gmt":"2026-09-23T03:22:09","guid":{"rendered":"https:\/\/www.oxygenworldwide.com\/?p=5942"},"modified":"2026-09-17T15:34:40","modified_gmt":"2026-09-17T15:34:40","slug":"cluster-headache-breakthrough-makes-history","status":"publish","type":"post","link":"https:\/\/www.oxygenworldwide.com\/fr\/cluster-headache-breakthrough-makes-history\/","title":{"rendered":"Neurostimulation for Chronic Cluster Headache: What Has Changed Since 2023? [Updated Sept 2026]"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><div data-parent=\"true\" class=\"vc_row row-container\" id=\"row-unique-0\"><div class=\"row limit-width row-parent\"><div class=\"wpb_row row-inner\"><div class=\"wpb_column pos-top pos-center align_left column_parent col-lg-12 single-internal-gutter\"><div class=\"uncol style-light\"  ><div class=\"uncoltable\"><div class=\"uncell no-block-padding\" ><div class=\"uncont\" ><div class=\"uncode_text_column\" ><\/p>\n<h2><span style=\"font-weight: 400;\">Quick Summary<\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In 2023, an Australian patient became the first person to receive Salvia BioElectronics&#8217; ultra-thin implant as part of early research into neuromodulation for severe headache disorders.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cluster headache and migraine are separate neurological conditions.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Research has continued, including a new Dutch study called RESPONSE-II investigating the treatment in people with chronic cluster headache.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The device remains investigational. It is not an approved treatment and there is not yet enough evidence to know how effective it will prove to be.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Established treatments remain important. European guidelines continue to strongly recommend high-flow 100% oxygen as one option for treating acute cluster headache attacks.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">When we first reported on a new neurostimulation implant in 2023, it was genuinely an interesting moment in cluster headache research.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A 29-year-old woman in Australia had become the first patient to receive an ultra-thin implant developed by Dutch medical technology company <\/span><a href=\"https:\/\/www.salviabioelectronics.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Salvia BioElectronics<\/span><\/a><span style=\"font-weight: 400;\">. Early reports from the company described improvements in the frequency and intensity of her attacks.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Three years later, we can look at that development with a little more perspective.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The technology has not become a standard cluster headache treatment. Nor can it be described as a cure. What has happened, however, is arguably more interesting: clinical research has continued, and a new study is now investigating the technology specifically in people with chronic cluster headache.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">So where does the research stand in 2026?<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">First, cluster headache is not a type of migraine<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">This is an important correction to our original 2023 article.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cluster headache and migraine can both cause severe head pain, but cluster headache is not a severe form of migraine. It is a separate primary headache disorder with its own characteristic symptoms and patterns.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cluster headache attacks tend to cause extremely severe pain on one side of the head, frequently around or behind one eye. They may be accompanied by symptoms such as watering of the eye, nasal congestion, a drooping eyelid or facial sweating.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Another characteristic is the pattern. Attacks can occur repeatedly, sometimes several times within 24 hours, and may follow remarkably regular daily or seasonal cycles.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">People with chronic cluster headache have an especially difficult form of the condition because they do not experience the long periods of remission associated with episodic cluster headache.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For a more detailed patient-focused explanation of the condition, <\/span><a href=\"https:\/\/myclusters.nl\/what-are-cluster-headaches\/?utm_source=oxygenworldwide.com\"><span style=\"font-weight: 400;\">MyClusters has a useful introduction to what cluster headaches are<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That distinction matters when discussing new research. A treatment being studied for migraine cannot automatically be assumed to work for cluster headache, and vice versa.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What is neurostimulation?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Neurostimulation uses controlled electrical impulses to influence activity in specific nerves.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This is not a completely new idea. Different forms of nerve stimulation have already been investigated for a range of neurological conditions. What made the Salvia development unusual was the design of the system.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The company&#8217;s current<\/span> <a href=\"https:\/\/www.salviabioelectronics.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">MySalvia Therapy<\/span><\/a><span style=\"font-weight: 400;\"> uses very thin implants positioned beneath the skin around targeted nerve areas in the forehead and back of the head. An external wearable device is then used to activate the stimulation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The intention is to target nerve pathways thought to be involved in severe headache disorders.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For someone living with frequent chronic cluster headache attacks that have not responded adequately to conventional treatment, it is easy to understand why this approach attracts attention.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">But that is also where caution becomes important.\u00a0 An interesting mechanism and an encouraging result in one patient are not the same as evidence that a treatment is effective across a wider group of people.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What actually happened in 2023?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Salvia BioElectronics announced its first implantation in July 2023.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The procedure involved the implantation of ultra-thin bioelectronic foils as part of the company&#8217;s early clinical research. The first patient was a 29-year-old woman in Australia who had lived with debilitating headaches since adolescence.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The company subsequently reported an immediate improvement in the number and intensity of her attacks.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That was clearly encouraging for the patient involved. It also represented an important technical milestone for the researchers. However, it was still the experience of the first patient.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Our original article described the event as a breakthrough. Looking back from 2026, a better description would be an important first step in establishing whether this form of neuromodulation could eventually become useful for some people with difficult-to-treat headache disorders.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The next question was always going to be whether the results could be reproduced in more patients.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What has happened to the cluster headache research since then?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The research programme has continued.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Salvia now lists its original 2023 RESPONSE study in Australia as its first evaluation of the therapy in people with chronic cluster headache. Recruitment for that study has finished, although the therapy remains under investigation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">More significantly for cluster headache research, a second study began in the Netherlands in March 2026.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Called <\/span><b>RESPONSE-II<\/b><span style=\"font-weight: 400;\">, the study is investigating combined trigeminal and occipital nerve stimulation as a preventive treatment for chronic cluster headache.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to the<\/span> <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07113470\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">current RESPONSE-II clinical trial record<\/span><\/a><span style=\"font-weight: 400;\">, up to 15 participants are expected to take part across two centres in the Netherlands. The study is aimed at people with chronic cluster headache who have not responded adequately to verapamil.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Researchers are looking at safety, potential clinical benefit and the experience of participants using the system.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">You can also see the current programme on <\/span><a href=\"https:\/\/www.salviabioelectronics.com\/clinical-studies\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Salvia BioElectronics&#8217; clinical studies page<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That is meaningful progress from where the story stood in 2023.\u00a0 But we need to say that it is also still early-stage research.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Does this mean an implant is now available for cluster headaches?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">No and this is probably the most important practical point.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Salvia itself describes MySalvia Therapy as an investigational device. It has not been approved for general commercial use, and the company states that it is not yet making claims about its safety or effectiveness.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">RESPONSE-II is a feasibility study. Its purpose is to generate evidence, not to demonstrate that the question has already been answered.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">We therefore cannot say at this stage whether the treatment will eventually be suitable for a wider group of people with chronic cluster headache.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Important questions remain.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">How much can treatment reduce attack frequency?<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Does it reduce attack severity?<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">How consistent is the effect between patients?<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">How well is the implant tolerated?<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Does any improvement continue over the longer term?<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">And perhaps most importantly, which people with chronic cluster headache, if any, are most likely to benefit?<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Those answers require clinical evidence.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Where does oxygen fit into cluster headache treatment?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">While experimental treatments attract understandable interest, they should not distract from the treatments already used in clinical practice.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The <\/span><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.15956\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">European Academy of Neurology&#8217;s guideline on cluster headache<\/span><\/a><span style=\"font-weight: 400;\"> makes a strong recommendation for 100% oxygen at a flow of at least 12 litres per minute as one treatment for acute cluster headache attacks. Subcutaneous sumatriptan is another strongly recommended acute treatment.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The precise treatment an individual uses should, of course, be decided with their neurologist or headache specialist.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Oxygen has a particular role because it is an acute treatment. It is used when an attack begins rather than as a preventive treatment designed to stop future attacks occurring.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That also explains why cluster headache oxygen can present unusual practical problems when travelling.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Someone might not require oxygen continuously, yet when an attack occurs they may need access to a high continuous flow immediately. A small portable oxygen concentrator designed for low-flow or <\/span><span style=\"font-weight: 400;\">pulse-dose oxygen may therefore be completely inappropriate for that particular prescription.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If you already use prescribed high-flow oxygen and are considering travelling, our guide to\u00a0 <\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/high-flow-oxygen-cluster-headaches-travel\/\"><span style=\"font-weight: 400;\">High Flow Oxygen for Cluster Headaches: Can You Travel Without Worry?<\/span><\/a><span style=\"font-weight: 400;\"> explains the practical issues in much greater detail.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">We also have a broader guide to <\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/travelling-high-flow-oxygen\/\"><span style=\"font-weight: 400;\">travelling with high-flow oxygen<\/span><\/a><span style=\"font-weight: 400;\"> if your oxygen requirements are more complex.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Research is not only about new treatments<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">New implants naturally attract headlines, but another part of cluster headache research is much less dramatic: understanding what happens to people between hospital appointments.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">When do attacks occur?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">How long do they last?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Are patterns changing?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">What treatments were used during individual attacks?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Are there seasonal or daily patterns that only become apparent when attacks are recorded over time?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This is one reason we have recently started working with <\/span><a href=\"https:\/\/myclusters.nl\/?utm_source=oxygenworldwide.com\"><span style=\"font-weight: 400;\">MyClusters<\/span><\/a><span style=\"font-weight: 400;\">, a patient-focused cluster headache tracking and research platform.\u00a0 MyClusters enables people to record their attacks and analyse their own patterns, while users can also choose to contribute anonymised data to research.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The importance of recording attacks is explained particularly well in the MyClusters article <\/span><a href=\"https:\/\/myclusters.nl\/blog\/cluster-headache-tracking\/?utm_source=oxygenworldwide.com\"><span style=\"font-weight: 400;\">Why Track Your Cluster Headaches?<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For someone living with an unpredictable condition, tracking does not make the attacks disappear. But having a reliable record can make it easier to discuss patterns, treatment responses and changes with a healthcare professional.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It can also give researchers access to something that is difficult to reproduce in a clinical setting: detailed information about how cluster headaches behave in everyday life.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What should we watch for next?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The important development since our original 2023 article is not that neurostimulation has &#8220;solved&#8221; cluster headache.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It has not.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The important development is that an intriguing first procedure has progressed into a continuing clinical research programme.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">RESPONSE-II should help researchers learn more about whether combined stimulation of targeted nerve areas can offer meaningful preventive benefit for people living with chronic cluster headache who have not responded adequately to established treatments.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That is exactly the sort of evidence that was missing when the first patient story appeared in 2023.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Until stronger results become available, the sensible position is one of cautious interest.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For people living with cluster headaches today, good specialist care, an appropriate acute and preventive treatment plan, and practical preparation remain essential.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">And if prescribed high-flow oxygen forms part of that treatment and you would like to travel, planning ahead makes an enormous difference.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">OxygenWorldwide can check what oxygen can be arranged at your destination, coordinate with your hotel, apartment or private accommodation, organise delivery and collection, and help plan refills where the service is available.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If this is your first time arranging oxygen away from home, you can also read our guide to <\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/services\/oxygen-travel\/\"><span style=\"font-weight: 400;\">travelling abroad with medical oxygen<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">When you are ready to plan your trip, <\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/contact\/enquiries\/\"><span style=\"font-weight: 400;\">fill in the OxygenWorldwide travel form<\/span><\/a><span style=\"font-weight: 400;\"> with your destination, dates and existing oxygen requirements and we will guide you from there.<br \/>\n<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Key Takeaways<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The neurostimulation story that began with the first Salvia implant in 2023 has developed into a genuine clinical research programme, including the RESPONSE-II chronic cluster headache study launched in the Netherlands in 2026. That is encouraging, but the technology remains investigational and should not yet be described as an established treatment or a cure.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For people living with cluster headache today, current treatment and good preparation remain more immediately relevant. <\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/high-flow-oxygen-cluster-headaches-travel\/\"><span style=\"font-weight: 400;\">High-flow oxygen<\/span><\/a><span style=\"font-weight: 400;\"> continues to have an established role in treating acute attacks when prescribed by a healthcare professional, while<\/span><a href=\"https:\/\/myclusters.nl\/blog\/cluster-headache-tracking\/?utm_source=oxygenworldwide.com\"> <span style=\"font-weight: 400;\">tracking attacks through resources such as MyClusters<\/span><\/a><span style=\"font-weight: 400;\"> can provide useful information about patterns and treatment response.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If prescribed oxygen is part of your treatment and you are planning a trip, <\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/contact\/enquiries\/\"><span style=\"font-weight: 400;\">fill in the OxygenWorldwide travel form<\/span><\/a><span style=\"font-weight: 400;\"> early so the destination arrangements can be checked properly.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Frequently Asked Questions<\/span><\/h2>\n<h3><b>Is neurostimulation an approved treatment for chronic cluster headache?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The Salvia system discussed in this article is currently investigational and is being evaluated through clinical studies. It should not be regarded as an approved, generally available treatment for chronic cluster headache.<\/span><\/p>\n<h3><b>Is the Salvia implant a cure for cluster headache?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">No. There is currently no evidence that supports describing the implant as a cure. Researchers are investigating whether this type of nerve stimulation can reduce the frequency or severity of attacks in selected people with chronic cluster headache.<\/span><\/p>\n<h3><b>What is the RESPONSE-II cluster headache study?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">RESPONSE-II is a clinical feasibility study that began in the Netherlands in March 2026. It is investigating combined trigeminal and occipital nerve stimulation in people with chronic cluster headache who have not responded adequately to verapamil. Up to 15 participants are expected to take part. The<\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07113470\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">RESPONSE-II study record is available on ClinicalTrials.gov<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h3><b>Does neurostimulation replace oxygen treatment?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">No. These are different approaches. Neurostimulation is being investigated as a preventive treatment, while high-flow oxygen is an established acute treatment used when a cluster headache attack occurs. Your neurologist or headache specialist should determine which treatments are appropriate for you.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Our article on<\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/high-flow-oxygen-cluster-headaches-travel\/\"> <span style=\"font-weight: 400;\">high-flow oxygen for cluster headaches and travel<\/span><\/a><span style=\"font-weight: 400;\"> explains the practical implications for people who already have prescribed oxygen.<\/span><\/p>\n<h3><b>Can I travel if I use high-flow oxygen for cluster headaches?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Often, yes, provided suitable oxygen can be arranged at your destination. High-flow cluster headache treatment has particular equipment and supply requirements, so arrangements should be checked well before travel.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">OxygenWorldwide does not provide oxygen inside aircraft cabins or at airports, but can arrange destination oxygen in many locations where the required service is available.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The best starting point is to<\/span><a href=\"https:\/\/www.oxygenworldwide.com\/en\/contact\/enquiries\/\"> <span style=\"font-weight: 400;\">complete the OxygenWorldwide travel form<\/span><\/a><span style=\"font-weight: 400;\"> with your destination, dates and prescribed oxygen requirements.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Summary<\/span><\/h2>\n<p><i><span style=\"font-weight: 400;\">Neurostimulation is being investigated as a possible preventive treatment for people with chronic cluster headache who have not responded adequately to established therapies. Salvia BioElectronics first implanted its ultra-thin neurostimulation system in 2023 and began the RESPONSE-II feasibility study in the Netherlands in March 2026. The technology remains investigational and is not an approved treatment or cure. Established treatments therefore remain important, including high-flow oxygen for acute attacks when prescribed by a healthcare professional. Attack tracking through platforms such as MyClusters may also help patients and researchers understand patterns and treatment responses.<\/span><\/i><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><script id=\"script-row-unique-0\" data-row=\"script-row-unique-0\" type=\"text\/javascript\" class=\"vc_controls\">UNCODE.initRow(document.getElementById(\"row-unique-0\"));<\/script><\/div><\/div><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"Quick Summary In 2023, an Australian patient became the first person to receive Salvia BioElectronics&#8217; ultra-thin implant as part of [...]","protected":false},"author":7,"featured_media":5943,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"iawp_total_views":53,"footnotes":""},"categories":[2,18,65,177],"tags":[91,162,192,959],"class_list":["post-5942","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-english","category-health","category-medical-oxygen","category-news","tag-health-2","tag-medical","tag-cluster-headaches","tag-migraines"],"_links":{"self":[{"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/posts\/5942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/comments?post=5942"}],"version-history":[{"count":5,"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/posts\/5942\/revisions"}],"predecessor-version":[{"id":29129,"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/posts\/5942\/revisions\/29129"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/media\/5943"}],"wp:attachment":[{"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/media?parent=5942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/categories?post=5942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oxygenworldwide.com\/fr\/wp-json\/wp\/v2\/tags?post=5942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}